Follow-The-Filings

Security · featured owners

AQST Aquestive Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.5%
  • $3M
  • 1 add

AQST (Aquestive Therapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (0.51%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.5% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel add 0.51%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.51% Add +75.3% 645,915 $3M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 8 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B3 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 1.01,1.02,2.02,2.03,3.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 16 rows shown

Filed Form Detail Links
4 Period Sep 15, 2026 Filing Doc
4 Period Sep 9, 2026 Filing Doc
4 Period Sep 9, 2026 Filing Doc
4 Period Sep 8, 2026 Filing Doc
4 Period Sep 3, 2026 Filing Doc
4 Period Aug 17, 2026 Filing Doc
4 Period Aug 14, 2026 Filing Doc
4 Period Jul 15, 2026 Filing Doc
4 Period Jun 23, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc
4 Period Jun 10, 2026 · 6 forms Filing Doc
4 Period Jun 8, 2026 Filing Doc
4 Period May 18, 2026 Filing Doc
4 Period May 15, 2026 · 2 forms Filing Doc
4 Period May 7, 2026 Filing Doc
4 Period May 5, 2026 · 4 forms Filing Doc

Updated about 16 hours ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $50.58M $57.56M $44.54M
Gross profit * $29.75M $39.69M $25.99M
Gross margin * 58.8% 69.0% 58.3%
Net income -$7.87M -$44.14M -$83.78M
Net margin * -15.6% -76.7% -188.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $40.97M $88.22M $149.27M
Total non-current assets * $16.45M $13.2M $11.16M
Total assets $57.42M $101.42M $160.42M
Total current liabilities $18.31M $18.86M $47.61M
Total non-current liabilities * $145.6M $142.72M $146.48M
Total equity -$106.49M -$60.16M -$33.66M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$6.38M -$35.76M -$52.43M
Cash from investing -$995,000 -$159,000 -$562,000
Cash from financing $3.97M $83.59M $102.62M
Net change in cash -$3.4M $47.67M $49.62M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders